Literature DB >> 34302746

Dapagliflozin in patients with COVID-19: truth or dare.

Xavier Rossello1, Francisca Caimari2.   

Abstract

Entities:  

Year:  2021        PMID： 34302746     DOI： 10.1016/S2213-8587(21)00206-0

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  2 in total

Review 1.  Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review.

Authors:  Elías Delgado; Esteban Jódar; Pedro Mezquita-Raya; Óscar Moreno-Pérez
Journal:  Diabetes Ther       Date:  2022-06-15       Impact factor: 3.595

Review 2.  Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations.

Authors:  Thiago Bosco Mendes; Alexandre Barbosa Câmara-de-Souza; Bruno Halpern
Journal:  Diabetol Metab Syndr       Date:  2022-03-04       Impact factor: 3.320
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.